Related Experiment Videos
Effects of ketanserin on left ventricular hypertrophy in hypertensive patients
Insights
Ketanserin effectively reduced left ventricular mass in hypertensive patients, demonstrating sustained regression of left ventricular hypertrophy (LVH) and preserving cardiac function over 12 months.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertension is a significant risk factor for left ventricular hypertrophy (LVH).
- LVH is associated with increased cardiovascular morbidity and mortality.
- Serotonergic S2-receptor antagonists represent a potential therapeutic avenue for managing hypertensive cardiac remodeling.
Purpose of the Study:
- To evaluate the efficacy of ketanserin in reducing left ventricular mass in hypertensive patients with ECG-defined LVH.
- To assess the long-term effects of ketanserin monotherapy on left ventricular structure and function.
Main Methods:
- Prospective study involving nine hypertensive patients with LVH.
- Echocardiographic measurements (M-mode) were performed at baseline (placebo), and after 3, 6, and 12 months of ketanserin treatment.
- Ketanserin was administered as monotherapy at a mean dose of 31 mg twice daily.
Main Results:
- Ketanserin treatment led to a significant decrease in mean left ventricular mass: 15.3% at 6 months (p<0.008) and 26.2% at 12 months (p<0.02).
- A non-significant trend towards improved left ventricular ejection fraction was observed.
- The observed regression of LVH was sustained throughout the 12-month treatment period.
Conclusions:
- Ketanserin demonstrates a sustained efficacy in promoting the regression of left ventricular hypertrophy in hypertensive patients.
- The drug appears to preserve left ventricular function during treatment.
- Ketanserin is a viable therapeutic option for managing hypertensive cardiac remodeling.
Abstract:
Ketanserin, a serotonergic S2-receptor antagonist, was used in a prospective study in nine hypertensive patients with ECG criteria of left ventricular hypertrophy (LVH). Echocardiographic measurement with M mode was made after 1 month of placebo, and after 3, 6, and 12 months of ketanserin treatment as monotherapy at a mean dose of 31 mg bid. Ketanserin treatment decreased mean left ventricular mass by 9.3% at 3 months (not significant), by 15.3% at 6 months (p less than 0.008), and by 26.2% at 12 months (p less than 0.02), with a tendency towards improvement in left ventricular ejection fraction, which was not statistically significant. The study showed a sustained effect upon regression of LVH in hypertensives, with preservation of left ventricular function.